Guardant Health: to present data at ESMO 2021 to demonstrate the utility of Guardant360 liquid biopsy for obtaining comprehensive molecular information to guide target treatment options for stage …

Guardant Health: to present data at ESMO 2021 to demonstrate the utility of Guardant360 liquid biopsy for obtaining comprehensive molecular information to guide target treatment options for stage …
Guardant Health: to present data at ESMO 2021 to demonstrate the utility of Guardant360 liquid biopsy for obtaining comprehensive molecular information to guide target treatment options for stage …

GuardantINFORM ™ Clinical Genomic Liquid Biopsy Dataset Highlights Need for Improved Treatment of Metastatic Colorectal Cancer Targeting the HER2 Gene

Guardant Health to Present Data Demonstrating Usefulness of Guardant360 Liquid Biopsy at ESMO 2021® to obtain comprehensive molecular information to guide targeted treatment options for advanced stage cancers

Guardant Health, Inc. (Nasdaq: GH), and leading academic institutions and pharmaceutical companies to share data highlighting molecular targets of importance, patterns of treatment resistance, and benefits of using the liquid biopsy Guardant360® to help improve the management of advanced solid cancers, at the European Society for Medical Oncology (ESMO) Virtual Congress 2021 to be held from September 16 to 21.

“While precision oncology has greatly contributed to improved clinical outcomes for very common cancers, such as non-small cell lung cancer, colorectal cancer and breast cancer, it remains a subset of patients who do not respond to currently available treatments, ”said Craig Eagle, MD, chief medical officer of Guardant Health. “It is gratifying to be able to work with the oncology community to analyze the molecular information generated by our liquid biopsy tests in order to continue to improve our understanding of possible new targets and more personalized treatments potentially capable of more constructively improving survival. of these patients with difficult-to-treat cancers. ”

Guardant INFORM ™ Liquid Biopsy Data Set Shows No Clear Standard of Care and Unmet Need for Patients with HER2 + Metastatic Colorectal Cancer




Characteristics and treatment patterns among patients with HER2-amplified advanced/metastatic colorectal cancer (mCRC): A clinical-genomic database study [Caractéristiques et schémas thérapeutiques chez les patients atteints d’un cancer colorectal avancé/métastatique (CCRm) avec amplification du gène HER2 : Une étude de base de données clinico-génomique]


John Strickler

Guardant360® Liquid Biopsy Reveals Molecular Insights Impacting Outcomes in Patients with Unresectable and Early-Onset (<50 years) Metastatic Colorectal Cancer [La biopsie liquide Guardant360® révèle des informations moléculaires ayant un impact sur les résultats des patients atteints d’un cancer colorectal métastatique non résécable et à déclenchement précoce (< 50 ans)]




Molecular features in liquid biopsy of early (EO) and late-onset colorectal cancer (LO)


Julia Alcaide-Garcia

Mutational landscape in synchronous unresectable metastatic colorectal cancer (mCRC) according to upfront primary tumour resection (UPTR) [Paysage mutationnel dans le cancer colorectal métastatique (CRCm) synchrone non résécable en fonction de la résection initiale de la tumeur primitive]


Manuel Benavides

Guardant360® Liquid Biopsy Reveals Treatment Resistance Patterns and Therapeutic Targets for the Management of Advanced Cancers Including Non-Small Cell Lung and Pancreatic including non-small cell lung cancer and pancreatic cancer)




First-results of the CLIMB360 study, a prospective molecular screening program across multiple cancer types based on circulating tumor DNA (ctDNA) [Premiers résultats de l’étude CLIMB360, un programme de dépistage moléculaire prospectif de plusieurs types de cancer sur la base de l’ADN tumoral circulant (ADNtc)]


Javier Garcia-Corbacho

Pre-existing and acquired mechanisms of resistance to lorlatinib in previously treated patients (pts) with ALK+ advanced non-small cell lung cancer (NSCLC)


Ben J. Solomon

Cell-free DNA dominant clone allele frequency associates with poor outcomes in advanced pancreatic cancer


Pedro Uson Junior

About Guardant Health

Guardant Health is a leading precision oncology company, which aims to help beat cancer on a global scale, through the use of its proprietary blood tests, large datasets and advanced analytics . The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient outcomes, and reduce healthcare costs across all stages of the cancer care continuum. Guardant Health commercially launched Guardant360 tests®, Guardant360 CDx, Guardant360 TissueNext ™, Guardant360 Response ™, as well as the GuardantOMNI tests® for patients with advanced cancer, and the Guardant Reveal ™ test for patients with early stages. These tests promote the development of its LUNAR screening program, the objective of which is to meet the needs of asymptomatic people eligible for cancer screening.

Forward-looking statements

This press release contains forward-looking statements within the meaning of Federal securities laws, including statements regarding the possibilities of use, and the potential values, benefits and advantages of Guardant Health’s liquid biopsy tests or trials, which involve risks and uncertainties likely to lead to a material difference between actual results and expected results or the expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual results could differ materially from these statements due to a number of factors. These risks and uncertainties, as well as others that may affect Guardant Health’s financial and operating results, and lead to actual results materially different from those indicated by the forward-looking statements in this press release, include those described under titles “Risk factors” and “Management’s discussion and analysis of the financial position and operating results” as well as in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, and in its other reports filed with the Securities and Exchange Commission, including its Quarterly Reports on Form 10-K for the fiscal year ended March 31, 2021 and for the fiscal year ended June 30, 2021. Forward-looking statements contained in this release press releases are based on information made available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to make update any forward-looking statements provided to reflect any change in its expectations, or any change in events, conditions or circumstances on which such statement is based, except as required by law. These forward-looking statements do not constitute a sufficiently reliable basis to represent the views of Guardant Health as of any date subsequent to the date of this press release.

The text of the press release resulting from a translation should in no way be considered official. The only authentic version of the press release is that of the press release in its original language. The translation will always have to be compared to the source text, which will set a precedent.

See the source version on

For Latest Updates Follow us on Google News

PREV the incidence rate increases by 252% in one week
NEXT of Lyonnais regenerate lost neurons